

CH. PERVAIZ ELAHI INSTITUTE OF CARDIOLOGY, MULTAN

MINUTES OF GRIEVANCES COMMITTEE MEETING

Agenda: Redressal of grievances received against technical evaluation of technical bids for the purchase of drugs / medicines through annual tender for the financial year 2023-24.

Venue: Conference Room, CPEIC Multan

Date & Time: Monday 25-05-2023 at 10:00 AM

1. The following officers / members of the committee attended the meeting.

- | | | |
|---|-----------------|-------|
| i. Prof. Dr. Tariq Abbas
Professor of Cardiology | Chairman | _____ |
| ii. Dr. Iftikhar Paras
Associate Professor of Cardiac Surgery | Member | _____ |
| iii. Dr. Muhammad Younas
Associate Professor of Paediatric Cardiology | Member | _____ |
| iv. Dr. M. Mustafa Ali Siddiqui
Associate Professor of Radiology | Member | _____ |
| v. Dr. Farhan Khan
Director Technical | Member | _____ |
| vi. Dr. Aamir Furqan
Assistant Professor of Anaesthesia | Member | _____ |
| vii. Dr. Fayyaz Ahmad Hashmi
PMO (Pathology Department) | Member | _____ |

2. The following aggrieved bidders or their representatives attended the meeting on behalf of their respective firms/companies (attendance of meeting attached).

- M/s Benson Pharmaceuticals (Pvt) Ltd.
- M/s Caraway Pharmaceuticals (Pvt) Ltd.
- M/s Genix Pharma (Pvt) Ltd.
- M/s Hiranis Pharmaceuticals (Pvt) Ltd.
- M/s Hudson Pharma (Pvt) Ltd.
- M/s Jamil Traders
- M/s Oncolink Pharma Distributor
- M/s S.J. & G. Fazul Ellahie (Pvt) Ltd.

3. The representatives of **M/s Benson Pharmaceuticals (Pvt) Ltd., M/s Hiranis Pharmaceuticals (Pvt) Ltd. & M/s Caraway Pharmaceuticals** presented that their quoted brands **Tab. Cardi, Tab. Rosuvast & Inj. A-Care respectively** failed to achieve qualifying marks in Technical Staff and Market Experience while their firms had supplied said brands in multiple government hospitals and attached purchase orders of the same. After discussion with members, the Chairman concluded that the Tab. Cardi & Tab. Rosuvast are to be used in CPEIC Multan in bulk quantity and Inj. A-Care in critical care / Anaesthesia department while end users of this institute have no previous experience of the quoted brand so firm is advised to provide sufficient quantity of samples to end users to establish a confident experience for further competition/recommendation in the next tender.

Decision: The committee unanimously decided to uphold the decision of Technical Evaluation Committee.

4. The representatives of following bidders presented that their rejected items were declared non-responsive because TEC granted less marks against parameter of technical staff / certification of the manufacture (**ordinary parameter no. 3 & 5**). They claimed that sufficient documents relating to the qualification of technical staff and certification were already attached with their bids however they have again provided the same with grievance submissions.

- i. **M/s Hudson Pharmaceuticals (Pvt) Ltd.**
- ii. **M/s S.J. & G. Fazul Ellahie (Pvt) Ltd.**

The Chairman forwarded the claim to the present members of Technical Evaluation Committee for reevaluation of their bids and additional documents submitted with the grievances. The members after diligent scrutiny of the bids and documents submitted in grievances, concluded that the attached documents were found still insufficient to achieve qualifying marks.

Decision: As the firms failed to prove qualifying marks even after reevaluation of bids and additional documents, the Grievances Committee unanimously decided to uphold the decision of Technical Evaluation Committee and rejected the appeal said firms.

5. The representatives of **M/s Genix Pharma (Pvt) Ltd.** presented that their bid was rejected as the firm failed to submit required tender samples and due to non-achieving qualifying marks in ordinary parameters and requested to allow receiving of tender samples and missing documents for re-evaluation.

Decision: The chairman and members of the committee disallowed to receive samples and missing documents at this stage of procurement process with the remarks that re-evaluation at this stage will cause further delay in tender conclusion and advised the aggrieved firm to provide sufficient quantity of samples to end users to establish an experience for further competition/recommendation in the next tender.

6. The grievance filed by **M/s Jamil Traders** against technical acceptance of **Inj. Xorbact 1g, Inj. Xorbact 2g & Inj. Cefiro 1g (tender Sr. No. 115, 116 & 117)** offered by **M/s New Majeed Medicine Company** was discussed. The representative of M/s Jamil Traders requested to re-evaluate the technical offer of said brand and objected that M/s New Majeed Medicine Company has mentioned that these stores are manufactured by Highnoon Laboratories Ltd. whereas actually these items are manufactured by Curexa Health (Pvt) Ltd. and said brands have no past experience of govt. institutions as well.

The technical offer and tender samples of said items were rechecked and the claim of M/s Jamil Traders was found justified. The members after detailed deliberation concluded that as the quoted brands have no significant past experience in govt. institutions and are not originally manufactured by Highnoon Laboratories itself, their technical evaluation status may be transposed from T.R to T.N.R.

Decision: The committee accepted that claim of M/s Jamil Traders and declared Inj. Xorbact 1g, Inj. Xorbact 2g & Inj. Cefiro 1g (tender Sr. No. 115, 116 & 117) offered by M/s New Majeed Medicine Company as Technically Non-Responsive


7. The grievance filed by **M/s Oncolink Pharma Distributors** against technical acceptance of **Inj. Efacurium (tender Sr. No. 184)** offered by **M/s Jamil Traders** was also discussed. The representative of M/s Oncolink Pharma requested to re-evaluate the technical offer of said brand and objected said brand possess comparatively less market / production experience and is not being used in renown teaching hospitals of Punjab.

The present members of Technical Evaluation Committee responded that Inj. Efacurium is currently being used in this institute and the clinical experience of end users is satisfactory against the quoted brand. Dr. Aamir Furqan, Assistant Professor of Anaesthesia and member of Grievance Committee also seconded the experience of Inj. Efacurium in CPEIC Multan.

Decision: The committee unanimously decided to uphold the decision of Technical Evaluation Committee and rejected the appeal of M/s Oncolink Pharma Distributor

12. The meeting ended by vote of thanks by the Chairman Grievances Committee.



Dr. Fayyaz Hashmi (Member)
PMO / Pathology Department
CPEIC Multan



Dr. Farhan Khan (Member)
Director Technical
CPEIC, Multan


Dr. M. Mustafa Ali Siddiqui (Member)
Associate Prof. of Radiology
CPEIC, Multan


Dr. Aamir Farqan (Member)
Assistant Prof. of Anaesthesia
CPEIC Multan


Dr. Iftikhar Paras (Member)
Associate Prof. of Cardiac Surgery
CPEIC, Multan


Dr. Muhammad Younas (Member)
Associate Prof. of Paediatric Cardiology
CPEIC, Multan


Prof. Dr. Tariq Abbas
Chairman, Grievances Committee
Prof. of Cardiology, CPEIC, Multan